CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 71 enrolled
Drug / intervention
EIDD-2801 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04405739
NCT04405739Phase 2Completed
CompareCT.gov

The Safety of EIDD-2801 and Its Effect on Viral Shedding of SARS-CoV-2

Ridgeback Biotherapeutics, LP·interventional·Posted May 28, 2020·Updated Mar 23, 2023

In Brief

A Phase 2 clinical trial evaluating EIDD-2801 and Placebo for SARS-CoV 2. Completed, enrolled 71 participants across 11 sites.

Detailed Summary

Designed as a multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of EIDD-2801 on SARS-CoV-2 Virus Shedding in Newly Hospitalized Adults with polymerase chain reaction (PCR)-Confirmed COVID-19.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV 2
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedMay 28, 2020
Enrollment StartJun 16, 2020
Primary CompletionFeb 21, 2022
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 6.1 years ago

Interventions

EIDD-2801drug

Oral capsule of EIDD-2801

Placebodrug

Oral placebo capsule